UBS Initiates Coverage On Biomarin Pharmaceutical with Buy Rating, Announces Price Target of $120
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Martin Auster has initiated coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy rating and a price target of $120.
September 18, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Biomarin Pharmaceutical with a Buy rating and a price target of $120, which could potentially drive the stock price up.
The initiation of coverage by UBS with a Buy rating indicates a positive outlook for Biomarin Pharmaceutical. The price target of $120, if higher than the current price, suggests that UBS believes the stock has room to grow, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100